161 related articles for article (PubMed ID: 38300452)
21. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
22. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
23. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract][Full Text] [Related]
24. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
25. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Schultz NM; O'Day K; Sugarman R; Ramaswamy K
J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
27. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
29. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
[TBL] [Abstract][Full Text] [Related]
30. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
[TBL] [Abstract][Full Text] [Related]
31. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
32. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
[TBL] [Abstract][Full Text] [Related]
33. Economic burden of follicular non-Hodgkin's lymphoma.
Foster T; Miller JD; Boye ME; Russell MW
Pharmacoeconomics; 2009; 27(8):657-79. PubMed ID: 19712009
[TBL] [Abstract][Full Text] [Related]
34. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
35. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
Ohno S; Shoji A; Hatake K; Oya N; Igarashi A
J Med Econ; 2020 Oct; 23(10):1130-1141. PubMed ID: 32620061
[TBL] [Abstract][Full Text] [Related]
40. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]